HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR , FOCUS and PICCOLO colorectal cancer trials

Richman, Susan D, Southward, Katie, Chambers, Philip, Cross, Debra, Barrett, Jennifer, Hemmings, Gemma, Taylor, Morag, Wood, Henry +11 more·2016·The Journal of Pathology
DOI 10.1002/path.4679

Cited by (241)

Items 101–200 of 241

  1. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features
    Jun Seok Park, Ghilsuk Yoon, Hye Jin Kim, Soo Yeun Park, Gyu‐Seog Choi, Min Kyu Kang, Jong Gwang Kim, Jung-Sik Jang, An Na Seo · 2018 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  2. Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues
    Canan Karan, Elaine S Tan, Humaira Rise Sarfraz, Todd Cory Knepper, Christine Marie Walko, Seth I. Felder, Richard D. Kim, İbrahim Halil Şahin · 2022 · JCO Oncology Practice
  3. Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
    Irene S. Yu, Francine Aubin, Rachel Anne Goodwin, Jonathan M. Loree, Cheryl A. Mather, Brandon S. Sheffield, Stephanie Leann Snow, Sharlene Gill · 2022 · Therapeutic Advances in Medical Oncology
  4. High levels of serum platelet-derived growth factor-AA and human epidermal growth factor receptor-2 are predictors of colorectal cancer liver metastasis
    Hongda Pan, Yi-Fan Peng, Gang Xiao, Jin Fa Gu · 2017 · World Journal of Gastroenterology
  5. Translational research of new developments in targeted therapy of colorectal cancer
    Lei Yang, N. E. Atakhanova, Meryelem Tania Churampi Arellano, Mohammed Yassen Mohamed, Thamer Hani, Ali A. Fahdil, Roxana Yolanda Castillo-Acobo, Ashima Juyal, Ahlam Kadhim Hussein, Ali H. Amin et al. · 2023 · Pathology - Research and Practice
  6. HER2-Positive Metastatic Colorectal Cancer
    Hannah Ruth Robinson, Wells A. Messersmith, Robert William Lentz · 2024 · Current Treatment Options in Oncology
  7. RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification
    Sun Mi Lee, Hyunjoo Oh · 2024 · Scientific Reports
  8. Advances and challenges in targeted therapies for HER2-amplified colorectal cancer
    Margot Pizzamiglio, Audrey Soulabaille, Widad Lahlou, Lorenzo Pilla, Aziz Zaanan, Julien Taı̈eb · 2025 · European Journal of Cancer
  9. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients
    Zhouhuan Dong, Linghong Kong, Zhiyi Wan, Fengwei Zhu, Mei Zhong, Yali Lv, Po Zhao, Huaiyin Shi · 2019 · Scientific Reports
  10. Personalized medicine in colorectal cancer.
    Padina Vaseghi Maghvan, Shabnam Jeibouei, Mohammad Esmael Akbari, Vahid Niazi, Farshid Karami, Alireza Rezvani, Nafiseh Ansarinejad, Masroor Abbasinia, Gisoo Sarvari, Hakimeh Zali et al. · 2020 · Gastroenterology and hepatology from bed to bench.
  11. The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
    Pina Ziranu, Eleonora Lai, Marta Schirripa, Marco Puzzoni, Mara Persano, Andrea Pretta, Giada Munari, Nicole Liscia, Valeria Pusceddu, Fotios Loupakis et al. · 2021 · Targeted Oncology
  12. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
    Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani, Francesca Battaglin, Francesca Bergamo, Lisa Salvatore, Arndt Stahler, Carlotta Antoniotti et al. · 2025 · Journal of Clinical Oncology
  13. Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges
    Tasuku Matsuoka, Masakazu Yashiro · 2021 · World Journal of Gastrointestinal Oncology
  14. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis
    Mengting Gao, Ting Jiang, Pengcheng Li, Jie Zhang, Ke Xu, Tao Ren · 2022 · Pharmacological Research
  15. A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
    Fnu Amisha, Paras Malik, Prachi Saluja, Nitesh Gautam, Tanvi Harishbhai Patel, Arya Mariam Roy, Sunny R. K. Singh, Sindhu Janarthanam Malapati · 2023 · Onco
  16. Racial disparities in colorectal cancer clinicopathological and molecular tumor characteristics: a systematic review
    Thomas Lawler, Lisa Parlato, Shaneda Warren Andersen · 2023 · Cancer Causes & Control
  17. Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer
    Marwan Fakih · 2018 · The Oncologist
  18. Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies
    Vaghi, Caterina, Tosi, Federica, Mauri, Gianluca, Bonazzina, Erica, Amatu, Alessio, Bencardino, Katia, Piscazzi, Daniele, Roazzi, Laura, Villa, Federica, Maggi, Michelangelo et al. · 2026 · Drugs
  19. Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer
    Nadia Saoudi Gonzalez, D. López-Valbuena, Diego Gómez, Javier Ros, Iosune Baraibar, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2022 · Expert Opinion on Drug Metabolism & Toxicology
  20. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer
    Rui Zhang, Chang Su, Yong-liang Jia, Menglu Xing, Shuiling Jin, Hong Zong · 2024 · Biomedicine & Pharmacotherapy
  21. Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H 2 Mab-181) Using Enzyme-Linked Immunosorbent Assay
    Teizo Asano, Junko Takei, Hiroyuki Suzuki, Mika Kato Kaneko, Yukinari Kato · 2021 · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
  22. Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
    Javier Torres-Jiménez, Jorge Esteban-Villarrubia, Reyes Ferreiro · 2022 · Cancers
  23. Comparing mutation calls in fixed tumour samples between the affymetrix OncoScan® array and PCR based next-generation sequencing
    Henry M. Wood, Joseph M. Foster, Morag Taylor, Emma Tinkler‐Hundal, Fiona S. Togneri, Paula Wojtowicz, Assa Oumie, Karen G. Spink, Fiona Brew, Philip Quirke · 2017 · BMC Medical Genomics
  24. Advances in the Development of Anticancer HSP-based Vaccines
    Alexey V. Baldin, Andrey A. Zamyatnin, Alexandr V. Bazhin, Wanhai Xu, Lyudmila V. Savvateeva · 2018 · Current Medicinal Chemistry
  25. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study
    Hisateru Yasui, Atsushi Takeno, Hiroki Hara, Hiroshi Imamura, Hiroki Akamatsu, Kazumasa Fujitani, Minoru Nakane, Chihiro Nakayama Kondoh, Seigo Yukisawa, Junichiro Nasu et al. · 2022 · International Journal of Colorectal Disease
  26. RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches
    Sütcüoğlu, Osman, Yıldırım, Hasan Çağrı, Almuradova, Elvina, Günenç, Damla, Yalçın, Şuayib · 2025 · Medicina
  27. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications
    Diana L. Hanna, Heinz‐Josef Lenz · 2016 · Expert Review of Clinical Pharmacology
  28. Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer
    Daniel H. Ahn, Daniel M. Walden, Tanios Bekaii‐Saab · 2022 · Expert Opinion on Investigational Drugs
  29. Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2
    Vinh A Dao, Gregory M. Heestand · 2023 · Current Problems in Cancer
  30. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
    Özkan Kanat, Hülya Ertaş, Burcu Caner · 2018 · World Journal of Clinical Cases
  31. Human epidermal growth factor receptor 2-positive digestive tumors
    Dorothea Wagner, Berna C. Özdemir, Josef Rüschoff · 2019 · Current Opinion in Oncology
  32. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
    Jaideep Singh Sandhu, Chongkai Wang, Marwan Fakih · 2020 · PubMed
  33. Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
    Yang Liu, Wenfei Li, Zhihao Lü, Ming Shian Lu, Jun Zhou, Zhi Peng, Xiaotian Zhang, Xicheng Wang, Lin Shen, Jian Li · 2022 · BMC Cancer
  34. Review of the Role of HER2/neu in Colorectal Carcinomas
    Lakshmi Sai Vijay Achalla, Raju Kamlakar Shinde, Sangita Jogdand, Sahitya Vodithala · 2022 · Cureus
  35. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer
    Imane El Dika, David H. Ilson · 2018 · Expert Review of Anticancer Therapy
  36. Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model
    Misagh Karimi, Chongkai Wang, Bahareh Bahadini, George Hajjar, Marwan Fakih · 2020 · Journal of Clinical Medicine
  37. HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study
    Alessandra Anna Prete, Valentina Angerilli, Francesca Bergamo, Valentina Vettore, Chiara De Toni, Rossana Intini, Krisida Cerma, Gianmarco Ricagno, Riccardo Cerantola, Eleonora Perissinotto et al. · 2024 · British Journal of Cancer
  38. Case 32-2018: A 36-Year-Old Pregnant Woman with Newly Diagnosed Adenocarcinoma
    Janet E. Murphy, Kimberly L. Shampain, Laura E. Riley, Jeffrey William Clark, Kristen M. Basnet · 2018 · New England Journal of Medicine
  39. Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management
    Aziz Alnakli, Abidali Mohamedali, Benjamin Heng, Charles Chan, Joo‐Shik Shin, Michael J. Solomon, Pierre H. Chapuis, Gilles J. Guillemin, Mark S. Baker, Seong Beom Ahn · 2024 · BJC Reports
  40. Distinct Clinicopathological Features and Prognostic Values of High-, Low-, or Non-Expressing HER2 Status in Colorectal Cancer
    Zehua Wu, Yi Cheng, Huaiming Wang, Dian Liu, Xiaoxing Qi, Chao Wang, Yuanzhe Zhang, Yuting Zhang, Runkai Cai, Hong Huo et al. · 2023 · Cancers
  41. Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
    Derrick S. Haslem, Hanlee P. Ji, James M. Ford, Lincoln D. Nadauld · 2017 · JCO Precision Oncology
  42. Development of a Novel Anti-HER2 Monoclonal Antibody H 2 Mab-181 for Gastric Cancer
    Junko Takei, Teizo Asano, Tomohiro Tanaka, Masato Sano, Hideki Hosono, Ren Nanamiya, Nami Tateyama, Masaki Saito, Hiroyoshi Suzuki, Hiroyuki Harada et al. · 2021 · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
  43. Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment
    Ghasem Noorkhajavi, Armin Banakholdi, Amirhosein Torabi, Amirreza Zoghi, Effat Iranijam, Elham Safarzadeh · 2025 · Cancer Cell International
  44. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy
    Nadia Saoudi Gonzalez, Paola Valeria Marchese, Iosune Baraibar, Javier Ros, Francesc Salvà, Marta Rodrı́guez, Clara Salvà, Caterina Vaghi, Adriana Alcaráz, Ariadna García et al. · 2024 · Expert Opinion on Investigational Drugs
  45. HER2 status in sinonasal intestinal-type adenocarcinoma
    Valeria Maffeis, Rocco Cappellesso, Alessia Zanon, Diego Cazzador, Enzo Emanuelli, Alessandro Martini, Ambrogio Fassina · 2019 · Pathology - Research and Practice
  46. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
    Qi Sun, Qi Li, Fuping Gao, Hongyan Wu, Yao Shi Fu, Jun Yang, Xiangshan Fan, Xiaobin Cui, Xiaohong Pu · 2022 · Journal of Cancer Research and Clinical Oncology
  47. Cibler HER2 dans le cancer colorectal
    Eléonore Spitzer, Pascale Cervera, Thierry André, Romain Cohen · 2023 · Bulletin du Cancer
  48. HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration
    Di Yang, Bo Wang, Yinuo Li, Jingyao Zhang, Xuantong Gong, Hao Qin, Yan Wang, Yahui Zhao, Yong Wang · 2023 · Biomedicines
  49. Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy
    Tania Fleitas, Carolina Martínez‐Ciarpaglini, Josefina Ayala, Cinthia Gauna, Rita Denis, Ita Yoffe, Silvia Sforza, María Teresa Martínez, Alicia Pomata, Maider Ibarrola‐Villava et al. · 2019 · Cancer Medicine
  50. ISH-based HER2 diagnostics
    Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, Oliver Stoß · 2020 · Der Pathologe
  51. Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation
    Chongkai Wang, Marwan Fakih · 2021 · Journal of the National Comprehensive Cancer Network
  52. Expression, clinical significance and correlation of RUNX3 and HER2 in colorectal cancer
    Yunshi Wu, Jun Xue, Yuanrui Li, Xueliang Wu, Ming Qu, Dandan Xu, Yongquan Shi · 2021 · Journal of Gastrointestinal Oncology
  53. Clinicopathological and prognostic significance of HER2 status in surgically resected colorectal liver metastases
    Jiahao Han, Xiangyu Wang, Chong Zhang, Qian Wu, Xiaochen Ma, Yitong Li, Zhenmei Chen, Rui Zhang, Guo Zhang, Jing Lin et al. · 2022 · Journal of Surgical Oncology
  54. Development and biological evaluation of 68Ga-labeled peptides for potential application in HER2-positive colorectal cancer
    Jinglin Zhang, Yixiang Lin, Jingyue Gao, Yuan Pan, Guihua Hou, Chun Guo, Feng Gao · 2024 · Bioorganic Chemistry
  55. Frequency of Her2-low in colorectal cancer and its relations with the tumor microenvironment
    Corinna Lang‐Schwarz, Michael W. Vieth, Theresa Dregelies, William Sterlacci · 2023 · Pathology - Research and Practice
  56. Successful treatment with trastuzumab plus chemotherapy as the first‑line regimen in advanced small bowel adenocarcinoma harboring HER2 amplification: A report of two cases
    Jingwen Wang, Xia Zhu, Jiayan Chen, Fei Liu, Xi Tang · 2023 · Oncology Letters
  57. Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm
    Carlotta Antoniotti, Roberto Moretto, Daniele Rossini, Gianluca Masi, Alfredo Falcone, Chiara Cremolini · 2020 · Cancer Treatment Reviews
  58. The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis
    Samantha M. Ruff, Alexander H. Shannon, Timothy Michael Pawlik · 2023 · Cancers
  59. SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin
    Guixia Pan, Danni Li, Xiao Li, Peng Ye, Tao Wang, Changjing Zuo · 2018 · Biochemical and Biophysical Research Communications
  60. An Update on the Role of Immunohistochemistry in the Evaluation of Pancreatic/Liver/Gastrointestinal Luminal Tract Disorders
    Jialing Huang, Guoli Chen, Hongjie Li · 2023 · Archives of Pathology & Laboratory Medicine
  61. Current status and perspectives of genetic testing in gastrointestinal cancer (Review)
    Tasuku Matsuoka, Masakazu Yashiro · 2023 · Oncology Letters
  62. Genetic and transcriptomic analyses of early-onset colon cancer (EOCC): a post hoc analysis of 2973 patients from two adjuvant randomized trials
    Annalice Gandini, Claire Gallois, Hélène Blons, Claire Mulot, Natacha Agueeff, Côme Lepage, Rosine Guimbaud, Laurent Mineur, Jérôme Desrame, Benoist Chibaudel et al. · 2024 · ESMO Gastrointestinal Oncology
  63. HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer
    Hai Luo, Lingzhi Cui, Kexin Shen, Ruiqi Li, Zeming Wang, Zhongshi Xie · 2021 · Cancer Management and Research
  64. Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer
    Flavia D’Angelo, Franck Monnien, Alexis Overs, Irvin Pem, Fanny Dor, Marine Abad, Sophie Adrian Felix, Zohair Selmani, Zaher Lakkis, Christophe Borg et al. · 2024 · Diagnostic Pathology
  65. Personalised medicine based on host genetics and microbiota applied to colorectal cancer
    Adriana González, Iker Badiola, Asier Fullaondo, Javier Rodríguez, Adrián Odriozola · 2024 · Advances in genetics
  66. Time to Deliver on Promises: The Role of ERBB2 Alterations as Treatment Options for Colorectal Cancer Patients in the Era of Precision Oncology
    S Buchholz, Nelia Nause, Ute Margarethe König, Johanna Reinecke, Benjamin Steuber, Christoph Ammer‐Herrmenau, Kirsten Reuter‐Jessen, Hanibal Bohnenberger, Lorenz Biggemann, Friederike Braulke et al. · 2023 · Journal of Personalized Medicine
  67. Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2
    YUZHI LIU, Evelyne Yehudit Bischof, ZHIQIN CHEN, JIAHUAN ZHOU, Bei Zhang, Ding Zhang, YONG GAO, Ming Quan · 2024 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
  68. Molecular-targeted Therapy for Precision Medicine in Gastrointestinal Cancer: Advancement in Cancer Targeting Strategies
    Rohitas Deshmukh, Shekhar Verma, Phool Singh Yaduwanshi, Anubhav Dubey, Mamta Kumari · 2025 · Current Cancer Drug Targets
  69. Protein Nanocarriers: Targeted Theranostics for Cancer Treatment and Imaging
    Reyhan Dilsu Colpan, Neil R. Thomas, Lyudmila Turyanska, Tracey Dawn Bradshaw · 2026 · Cancers
  70. Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib
    Piotr Kawczak, Tomasz Bączek · 2026 · Journal of Clinical Medicine
  71. Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes
    Jae Yeon Jang, Youngkyung Jeon, Sun Young Jeong, Sung Hee Lim, Young Suk Park, Ho Yeong Lim, Jee Yun Lee, Seung Tae Kim · 2023 · Journal of Gastrointestinal Oncology
  72. HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study
    Heba E. M. El-Deek, Moemen Hafez, Thanaa M.M. Sotouhy, Eman Mosaad Zaki, Hanan Ahmed Eltyb, Fatma M M Kamal · 2024 · Asian Pacific Journal of Cancer Prevention
  73. HER2-positive, RAS-mutant, MSS colorectal cancer: a rare subtype report and novel insights into immunotherapy and ADC combinations
    Xiaoyan Kong · 2025 · American Journal of Cancer Research
  74. Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis
    Svea Cheng, Cyndi Gonzalez Gomez, Morgan Ferrell, Richard J. Giza, Masood Pasha Syed, Tara Magge, Vikram C. Gorantla, Ronan Wenhan Hsieh, Riyue Bao, Aatur Dilip Singhi et al. · 2025 · The Oncologist
  75. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer
    Andrea Sartore Bianchi, Salvatore Siena · 2017 · Handbook of experimental pharmacology
  76. The Role of HER2 Testing in Advanced Colorectal Cancer
    Rutika Jitesh Mehta · 2018 · Current Colorectal Cancer Reports
  77. Current Perspective and Treatment Strategies in Targeted Therapy for Colorectal Cancer
    Pramod Kumar Maurya, Ashutosh Mani · 2024 · Clinical Cancer Drugs
  78. Combination Therapy of Trastuzumab and Lapatinib in Chemorefractory HER2-Positive Metastatic Colorectal Cancer: An Efficacy and Safety Analysis
    Xiaofeng Ma, Zhongsu Yu, Liangping Cheng, Shaoyan Wang · 2025 · International Journal of Pharmacology
  79. HER2: Biology, Definition, Diagnosis, and its Role in Cancers
    Mina Sadat Naderi, Fereshteh Ameli, Sahand Golestanian · 2025 · IntechOpen eBooks
  80. Therapeutic Intervention of Signaling Pathways in Colorectal Cancer
    Vikas Chandra, Ashutosh Tiwari, Rajat Pratap Singh, Kartiki Vasant Desai · 2022 · Springer eBooks
  81. Unraveling of inhibitory potential of phytochemicals against SARS-CoV-2 using in-silico approach
    Deepak Ganjewala, Hina Bansal, Ruchika Mittal, Gauri Srivastava · 2022 · Elsevier eBooks
  82. A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
    Aswanth Reddy, Nkolika Nwankwo, Arjun Sekar, Aswini Kumar · 2023 · Cureus
  83. Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
    Hannah E. Trembath, Jen Jen Yeh, Nicole Lopez · 2024 · Cancer treatment and research
  84. Patient-derived organoids reveal marked heterogeneity in chemosensitivity profiles of colorectal cancer and a potential association with HER2 status
    Jian Liu, Dan Xiao Li, Jing Li, Wenlan Fu, Qiang Jia, Yang Bai, Axiu Huang, Fang Chen · 2025 · Frontiers in Pharmacology
  85. Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer
    Ian Chau · 2021 · The Lancet Oncology
  86. Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT
    Louise Clare Brown, David J. Fisher, Richard Adams, Jenny F. Seligmann, Michel Seymour, Richard S. Kaplan, Susan D. Richman, Philip Quirke, Rachel Butler, Helen C. Roberts et al. · 2022 · Efficacy and Mechanism Evaluation
  87. Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer
    Zhiqin Chen, Jinde Chen, Yong Gao, Ming Quan · 2021 · Expert Review of Anticancer Therapy
  88. Mind the target: human epidermal growth factor receptor 2 in colorectal cancer
    Rita Saúde-Conde, Gertjan Rasschaert, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani · 2022 · Current Opinion in Oncology
  89. Molecular Oncology in Management of Colorectal Cancer
    Ramraj Nagendra Gupta Vemala, Sanjeev Vasudev Katti, Bhawna Sirohi, Divya Manikandan, Govind Nandakumar · 2021 · Indian Journal of Surgical Oncology
  90. Evaluation of immune infiltrate according to the HER2 status in colorectal cancer
    Chloé Molimard, Fanny Dor, Alexis Overs, Franck Monnien, Grégoire Gessain, Lois Kedochim-Augier, Flavia D’Angelo, Marine Abad, Morgane Heberle, Valentin Dérangère et al. · 2023 · Digestive and Liver Disease
  91. Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies
    Yajing Chi, Hongtu Yuan, Qing Fan, Zhendan Wang, Zuoxing Niu, Jinming Yu, Dandan Yuan · 2024 · Gene
  92. Systemic Therapy for Metastatic Colon Cancer: New Frontiers
    Yoanna S Pumpalova · 2024 · Clinics in Colon and Rectal Surgery
  93. A Case of Human Epidermal Growth Factor Receptor 2‐Positive Colon Cancer With Invasive Micropapillary Carcinoma Component
    Masashi Kono, Yoriaki Komeda, Hiroshi Kashida, Satoru Hagiwara, Akihiro Yoshida, Shunsuke Omoto, Mamoru Takenaka, Naoko Tsuji, George Tribonias, Masatoshi Kudo · 2025 · DEN Open
  94. Multiplexed Digital PCR Reference Gene Measurement for Genomic and Cell-Free DNA Analysis
    Dilek Yener, Eloise J. Busby, Jo Vandesompele, Gertjan Wils, Susan D. Richman, Henry M. Wood, Jim F. Huggett, Carole A. Foy, Alison S. Devonshire · 2025 · Cells
  95. Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals
    Veronica Serena Cabitza, Pier Cesare Capponi, Irene Brusa, Fabrizio Vincenzi, Silvia Pasquini, Katia Varani, Luca Urso, Licia Uccelli · 2026 · Molecular Diagnosis & Therapy
  96. Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report
    А. А. Качмазов, Л. В. Болотина, Anna L. Kornietskaya, Устинова Татьяна Васильевна, V. A. Tolstov, А. А. Феденко · 2019 · Meditsinskiy sovet = Medical Council
  97. Expression of Septin 2 and Her2/neu in Colorectal Cancer
    Hala El‐hanbuli, Samar Ibrahim Ismail Amer, Heba A. Ibrahim · 2021 · Journal of Microscopy and Ultrastructure
  98. Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice
    Carsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Richard Price, Shiraj Sen, Jessica Davies, Emily H. Castellanos, Jeremy Snider, Xiaobo Bai et al. · 2022 · JCO Clinical Cancer Informatics
  99. Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer
    Maria G. Fencer, Catherine H. Davis, Kristen Renee Spencer · 2022 · Current Colorectal Cancer Reports
  100. Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study
    Nan Chen, Changlong Li, Yi-Fan Peng, Yunfeng Yao · 2022 · World Journal of Gastrointestinal Oncology